New business information added
We have added an overview of our two new business initiatives, LISH-GENE® and Antibody Compass, to this website. Please see the "Featured Projects" section below for details.
Bringing biotechnology closer to you.
We have added an overview of our two new business initiatives, LISH-GENE® and Antibody Compass, to this website. Please see the "Featured Projects" section below for details.
We have updated our corporate website.
We carry out biotechnology-based service work for business companies. We have been involved in various research and development projects in collaboration with many companies, utilising our protein synthesis, PCR primer design and compound screening assay technologies.
As new initiatives, we are developing LISH-GENE®, an ultra-fast genetic analysis system that identifies pathogens simply and quickly on the spot, and Antibody Compass, a test that reads the early signs of disease from a single drop of blood. Both are core projects aimed at a society where patients can receive appropriate treatment with peace of mind.
Integrating advanced molecular biotechnology with computational science, we provide a comprehensive range of research and development support and contract services as a trusted partner for pharmaceutical companies, medical institutions, and research organisations. From cutting-edge gene expression analysis and protein engineering to the visualisation of immune ageing and the development of next-generation diagnostic systems, we deliver end-to-end biotech solutions to drive innovation.
Specifically, we operate our core businesses based on the following advanced technologies:
Among our core businesses, the following two initiatives are currently in active development. Here we share an overview of each; further details will be announced as the projects mature.
An on-demand microbiome analysis system
LISH-GENE® is an on-demand microbiome analysis system that combines ultra-fast PCR with our proprietary assay kits to identify pathogens and resident microbes on the spot, in minutes. Without sending samples to an external laboratory, it aims to detect multiple targets at once with speed and high sensitivity. From infectious disease to everyday settings such as dentistry and skincare, we envision genetic analysis becoming part of daily life — so anyone can easily check the state of their own body.
Details coming soon
Reading the early signs of disease from a single drop of blood
Antibody Compass is a testing service that measures multiple “predictive antibodies” from a single drop of blood taken at the fingertip, capturing changes in the body before symptoms appear. While a standard health check looks at present abnormalities and genetic testing reveals inherited risk, Antibody Compass focuses on the early buds of disease unfolding right now. By interpreting the results from multiple angles, it aims to give each person the chance to rethink their health at an early stage.
Details coming soon| Company Name | Celish FD, Inc. |
| CEO | Hirofumi Doi |
| Established | October 2007 |
| Location | Inohana Innovation Plaza, Chiba University #404, 1-8-15, Inohana, Chuo-ku Chiba 260-0856 JAPAN |
| Business | BtoB service business based on biotechnology |
| Hirofumi Doi | CEO, PhD |
| Haruyuki Kinoshita | Board Member, PhD |
| Takashi Kudo | Research Fellow, PhD |
| Yuichiro Nakamura | Adviser, PhD |
| Masahiro Matsuoka | Adviser |
Please feel free to contact us using the form below.